Login Register Cart 0
Review Article

NLS-3（左法派酯或（R，R）Phacetopoperane）：一种哌甲酯的反向酯：文献综述

卷 31, 期 9, 2024

发表于: 31 March, 2023

页: [1069 - 1081] 页: 13

弟呕挨: 10.2174/0929867330666230120161837

价格: $65

conference banner
摘要

背景：NLS-3或（R，R）phacetoperane（左法派酯）的对映体是哌甲酯的反向酯，哌甲酯是一种自20世纪50年代末以来被广泛用于治疗注意力缺陷/多动障碍（ADHD）的精神刺激剂。由Special Rhône Poulenc和Rhodia在加拿大和欧洲推出，名为Lidebran®（8228 R.P.），用于治疗肥胖和抑郁症，从1959年到1967年，白内障手术成为一种越来越受欢迎的精神病药物。先前的数据支持，法西他定的刺激作用不同于其他作用于儿茶酚胺系统的药物（如哌甲酯、苯丙胺），具有收益/风险平衡的优势。方法：本研究的目的是使用体外和体内分析来表征NLS-3的结合谱，并考虑所有可用数据来假设潜在的治疗用途。结果：与其他兴奋剂相比，一项完整的结合图谱分析证实了法西他定的潜在益处，其益处/风险更高。NLS-3合成是由苯酮合成的，苯酮也用于合成哌甲酯。它与Rhône Poulenc SA实验室使用的不同，允许对以前未合成的几种对映体进行个体化。本综述还证实了该化合物在近1000名儿童和青少年中的广泛临床应用，其大剂量范围的副作用与对照治疗相比较少。此外，研究发现，受试者对左晶状体操作术的总体耐受性良好。结论：NLS-3可能是ADHD患者更安全、更有效的兴奋剂替代品。

关键词: 嗜睡、嗜睡症、精神病、多动症、乏力、精神病症状。

« Previous Next »
[1]
Bradley, C. The behavior of children receiving benzedrine. Am. J. Psychiatry, 1937, 94(3), 577-585.
[http://dx.doi.org/10.1176/ajp.94.3.577]
[2]
Cortese, S.; Adamo, N.; Del Giovane, C.; Mohr-Jensen, C.; Hayes, A.J.; Carucci, S.; Atkinson, L.Z.; Tessari, L.; Banaschewski, T.; Coghill, D.; Hollis, C.; Simonoff, E.; Zuddas, A.; Barbui, C.; Purgato, M.; Steinhausen, H.C.; Shokraneh, F.; Xia, J.; Cipriani, A. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry, 2018, 5(9), 727-738.
[http://dx.doi.org/10.1016/S2215-0366(18)30269-4] [PMID: 30097390]
[3]
Wigal, T.L.; Newcorn, J.H.; Handal, N.; Wigal, S.B.; Mulligan, I.; Schmith, V.; Konofal, E. a double-blind, placebo- controlled, phase ii study to determine the efficacy, safety, tolerability and pharmacokinetics of a controlled release (CR) formulation of mazindol in adults with DSM-5 attention-deficit/hyperactivity disorder (ADHD). CNS Drugs, 2018, 32(3), 289-301.
[http://dx.doi.org/10.1007/s40263-018-0503-y] [PMID: 29557078]
[4]
Nageye, F.; Cortese, S. Beyond stimulants: A systematic review of randomised controlled trials assessing novel compounds for ADHD. Expert Rev. Neurother., 2019, 19(7), 707-717.
[http://dx.doi.org/10.1080/14737175.2019.1628640] [PMID: 31167583]
[5]
Polanczyk, G.; de Lima, M.S.; Horta, B.L.; Biederman, J.; Rohde, L.A. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am. J. Psychiatry, 2007, 164(6), 942-948.
[http://dx.doi.org/10.1176/ajp.2007.164.6.942] [PMID: 17541055]
[6]
Posner, J.; Polanczyk, G.V.; Sonuga-Barke, E. Attention-deficit hyperactivity disorder. Lancet, 2020, 395(10222), 450-462.
[http://dx.doi.org/10.1016/S0140-6736(19)33004-1] [PMID: 31982036]
[7]
Thorpy, M.J.; Hiller, G. The medical and economic burden of narcolepsy: Implications for managed care. Am. Health Drug Benefits, 2017, 10(5), 233-241.
[PMID: 28975007]
[8]
Konofal, É.; Dolitsky, D. ADHD andits medications, an illustrated history over time. Impulsion naturelle, 2019. Available from: http://impulsion-naturelle.fr/produit/ adhd-its-medications-an-illustrated-history-over/
[9]
Morton, W.A.; Stock, G.G. methylphenidate abuse and psychiatric side effects. Prim. Care Companion J. Clin. Psychiatry, 2000, 2(5), 159-164.
[http://dx.doi.org/10.4088/PCC.v02n0502] [PMID: 15014637]
[10]
Conners, C.K.; Eisenberg, L. The effects of methylphenidate on symptomatology and learning in disturbed children. Am. J. Psychiatry, 1963, 120(5), 458-464.
[http://dx.doi.org/10.1176/ajp.120.5.458] [PMID: 14051237]
[11]
Cortese, S.; Holtmann, M.; Banaschewski, T.; Buitelaar, J.; Coghill, D.; Danckaerts, M.; Dittmann, R.W.; Graham, J.; Taylor, E.; Sergeant, J. Practitioner Review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J. Child Psychol. Psychiatry, 2013, 54(3), 227-246.
[http://dx.doi.org/10.1111/jcpp.12036] [PMID: 23294014]
[12]
Sivadon, P. Chanoit; Azoulay. First clinical results of the use of a new psycho-tonic. The 8228 R.P. Ann. Med. Psychol. (Paris), 1959, II, 536-537.
[PMID: 13854835]
[13]
Konofal, E.; Figadere, B. Phacetoperane to treat attention deficit hyperactivity disorder. EP Patents EP2785344B1, 2016.
[14]
Thai, D.L.; Sapko, M.T.; Reiter, C.T.; Bierer, D.E.; Perel, J.M. Asymmetric synthesis and pharmacology of methylphenidate and its para-substituted derivatives. J. Med. Chem., 1998, 41(4), 591-601.
[http://dx.doi.org/10.1021/jm970620j] [PMID: 9484508]
[15]
Nahm, S.; Weinreb, S.M. N-methoxy-n-methylamides as effective acylating agents. Tetrahedron Lett., 1981, 22(39), 3815-3818.
[http://dx.doi.org/10.1016/S0040-4039(01)91316-4]
[16]
Dargazanli, G.; Estienne-Bouhtou, G.; Marabout, B.; Roger, P.; Sevrin, M. N-phenyl(piperidin-2-Yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy. EP Patent EP1527048A2, 2005.
[17]
Dewar, G.H.; Parfitt, R.T.; Sheh, L. Stereochemical features of reduction and elimination reactions of 8-emthyl-6-phenyl-8-azabicyclo(3.2.1)oct-6-ene (6-phenyl-6-tropene). Chem. Informationsd., 1985, 1, 16.
[18]
Pham, V.C.; Charlton, J.L. Methyl (S)-Lactate as a chiral auxiliary in the asymmetric synthesis of Bao Gong Teng A. J. Org. Chem., 1995, 60(24), 8051-8055.
[http://dx.doi.org/10.1021/jo00129a053]
[19]
Laboratoires specia. Lidepran: Psychoactive lidepran; Paris, 1963.
[20]
Ziolko, H.U. The significance of psychodynamic factors for the effect of phenylpiperidylcarbinol (Bayer 1313). Med. Exp. Int. J. Exp. Med., 1960, 2, 224-227.
[PMID: 13847609]
[21]
Michel, J.R.; Marie, J.N. New esters. US Patent US2928835A, 1960.
[22]
Ramirez, A.; Vial, H.; Barailler, J.; Pacheco, H. Effects of levophacetoperane, pemoline, fenozolone, and centrophenoxine on catecholamines and serotonin uptake in various parts of the rat brain. C.R. Acad. Hebd. Seances Acad. Sci. D, 1978, 187(1), 53-56.
[PMID: 29714]
[23]
Snyder, S.H.; Coyle, J.T. Regional differences in H3-norepinephrine and H3-dopamine uptake into rat brain homogenates. J. Pharmacol. Exp. Ther., 1969, 165(1), 78-86.
[PMID: 5782836]
[24]
Hanna, C.; Upton, P.D.; Chambers, W.F. Comparative effects of D-1 amphetamine and 1-phenyl-1-(piperidyl-2′)-1-acetoxy-1-methane (R.P. 8228) in antagonizing barbiturate hypnosis. Arch. Int. Pharmacodyn. Ther., 1963, 145, 553-564.
[PMID: 14067576]
[25]
Yung-Chi, C.; Prusoff, W.H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol., 1973, 22(23), 3099-3108.
[http://dx.doi.org/10.1016/0006-2952(73)90196-2] [PMID: 4202581]
[26]
Zlotos, D.P.; Bender, W.; Holzgrabe, U. Muscarinic receptor agonists and antagonists. Expert Opin. Ther. Pat., 1999, 9(8), 1029-1053.
[http://dx.doi.org/10.1517/13543776.9.8.1029]
[27]
Schenk, S.; Partridge, B. Sensitization to cocaine’s reinforcing effects produced by various cocaine pretreatment regimens in rats. Pharmacol. Biochem. Behav., 2000, 66(4), 765-770.
[http://dx.doi.org/10.1016/S0091-3057(00)00273-2] [PMID: 10973514]
[28]
Schenk, S.; Shippenberg, T.S.; Partridge, B. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology (Berl.), 1999, 144(4), 339-346.
[http://dx.doi.org/10.1007/s002130051016] [PMID: 10435406]
[29]
Schenk, S.; Partridge, B.; Shippenberg, T.S. Reinstatement of extinguished drug-taking behavior in rats: Effect of the kappa-opioid receptor agonist, U69593. Psychopharmacology (Berl.), 2000, 151(1), 85-90.
[http://dx.doi.org/10.1007/s002130000476] [PMID: 10958121]
[30]
Schenk, S.; Partridge, B. Cocaine-seeking produced by experimenter-administered drug injections: dose-effect relationships in rats. Psychopharmacology (Berl.), 1999, 147(3), 285-290.
[http://dx.doi.org/10.1007/s002130051169] [PMID: 10639687]
[31]
Morani, A.S.; Kivell, B.; Prisinzano, T.E.; Schenk, S. Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. Pharmacol. Biochem. Behav., 2009, 94(2), 244-249.
[http://dx.doi.org/10.1016/j.pbb.2009.09.002] [PMID: 19747933]
[32]
Spangler, R.; Zhou, Y.; Maggos, C.E.; Schlussman, S.D.; Ho, A.; Kreek, M.J. Prodynorphin, proenkephalin and κ opioid receptor mRNA responses to acute “binge” cocaine. Brain Res. Mol. Brain Res., 1997, 44(1), 139-142.
[http://dx.doi.org/10.1016/S0169-328X(96)00249-5] [PMID: 9030708]
[33]
Wee, S.; Koob, G.F. The role of the dynorphin–κ opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl.), 2010, 210(2), 121-135.
[http://dx.doi.org/10.1007/s00213-010-1825-8] [PMID: 20352414]
[34]
Groer, C.E.; Tidgewell, K.; Moyer, R.A.; Harding, W.W.; Rothman, R.B.; Prisinzano, T.E.; Bohn, L.M. An opioid agonist that does not induce mu-opioid receptor-arrestin interactions or receptor internalization. Mol. Pharmacol., 2007, 71(2), 549-557.
[http://dx.doi.org/10.1124/mol.106.028258] [PMID: 17090705]
[35]
Kivell, B.M.; Ewald, A.W.M.; Prisinzano, T.E.; Salvinorin, A. Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse. Adv. Pharmacol., 2014, 69, 481-511.
[http://dx.doi.org/10.1016/B978-0-12-420118-7.00012-3] [PMID: 24484985]
[36]
Simonson, B.; Morani, A.S.; Ewald, A.W.M.; Walker, L.; Kumar, N.; Simpson, D.; Miller, J.H.; Prisinzano, T.E.; Kivell, B.M. Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A. Br. J. Pharmacol., 2015, 172(2), 515-531.
[http://dx.doi.org/10.1111/bph.12692] [PMID: 24641310]
[37]
Butelman, E.R.; Kreek, M.J. Discriminative stimulus properties of opioid ligands: Progress and future directions. Curr. Top. Behav. Neurosci., 2016, 39, 175-192.
[http://dx.doi.org/10.1007/7854_2016_9] [PMID: 27225498]
[38]
Courvoisier, S. Étude des propriétés stimulantes centrales de l’acétoxy-l-phényl-l(pipéridyl-2′)-l-méthane, threo, levogyre (8228 R. P.). Ann. Med. Psychol. (Paris), 1959, 117, 345.
[39]
Fournier Michel. Contribution to the study of the effects of lidepran. In: Neuro-Psychiatrie Infantile; Faculty of Medicine of Paris: Paris, 1962.
[40]
Dobkin, A.B. Drugs which stimulate affective behavior. 2. Comparison of the analeptic effect of d’amphetamine, bemigride with amiphenazole, methylphenidylacetate, iproniazid (micoren) and RP8228. Anaesthesia, 1960, 15, 146-153.
[http://dx.doi.org/10.1111/j.1365-2044.1960.tb13319.x] [PMID: 13817063]
[41]
Bontronc, C.; Médecine, U. de P. About the psychotonics levophacetoperan and methylphenidate. The Psychoses and in Minor Psychoneurotic States; R. Vezin, 1961.
[42]
Salinger, R.J. Contribution to the experimental study of new psychoactive medications and their therapeutic use in psychiatry: about one of them: 8228 RP or phenyl-1 (piperidyl-2’) 1-acetoxy-methane threolevogyre hydrochloride. 1961.
[43]
Jean-Charles, B.; Trovero, F.; Figadere, B.; Akagah, B.; Konofal, E. [Examination of potential addictive effects of NLS-3, a new compound in development for ADHD]. 4th International Conference on ADHD, 16th-19th OctoberBerlin, Germany, 2016.
[44]
Sivadon, P.; Salinger, R.J.; Quidu, M. Clinical results of the use in psychiatry of a new psychotonic: the 8228 RP (about the first 134 observations). Reports of the Meetings of the Academy of Sciences (Paris), 1960, 760-769.
[45]
Sivadon, P. Salinger René. Ann. Med. Psychol. (Paris), 1962, 120, 824-832.
[PMID: 13913515]
[46]
Chanoit, P-F. Some considerations about the psychotherapeutic use of a new psychotonic. Ann. Med. Psychol. (Paris), 1960, 118, 869-878.
[PMID: 13692358]
[47]
Follin, S.; Chanoit, P-F.; Huchon, J. The use of a new psychotonic: The 8228 RP. In a hospital environment (assessment performed after two years of trials). Reports Meet. Acad. Sci., 1970, 770-776.
[48]
Guyotat, J.; Hochmann, J. The present status of RP-8228 in psychiatric therapeutics. Apropos of 32 recent cases. Lyon Med., 1962, 94, 777-783.
[PMID: 13951512]
[49]
Labaï, C. Clinical results and remarks drawn from the use of iproniazid, RP 82-28 and nialamide in a departmental psychiatric hospital setting; Print South West: Toulouse, 1961.
[50]
Oules, J.; Labaï, C. Therapeutic. Free Subjects: Indications and Use of a New Psychotonic: The 8228 RP. In: Proceedings of the Congress of Psychiatry and Neurology in the French Language Lille, 1960.
[51]
Garde, A. Results obtained with 8.228 R.P. after two years of use of this psychotonic. Lyon Med., 1962, 94, 1549-1555.
[PMID: 13896864]
[52]
Deshaies, G.; Fontaine, C.; Spelz, M.T. Use of a psychotonic in psychiatry. Ann. Med. Psychol. (Paris), 1965, 123, 630-637.
[PMID: 14296669]
[53]
Grimberg, L.; Grimberg-Pivet, S. Psychiatry. Therapeutic. Intervention: Thoughts on the clinical use of 8228 RP. Or levophacetoperane (Lidepran). Proc. Congr. Psychiatry Neurol. French Lang., 1965, 1, p. 812.
[54]
Faure, H.; Faure, M.L. Les Apports Du Nozinan. Neuro-Psychiatrie Infantile (Levomépromazine, 70.44. RP.). Psychological and Sociological Problems in Imbecility; Karger Publishers: Switzerland ; , 1963, pp. 160-164.
[55]
Beaujard, M.; Revol, E. Clinical tests of the activity of RP 8228 (phacetoperane) in an oligophrenic child. Pediatrie, 1960, 15, 310-316.
[PMID: 13797965]
[56]
Guyotat, J.; Beaujard, M.; Guillaumin, J. Psychometric Evaluation of the Effects of a Psychotonic, 8.228R.P. Methodological Considerations. Communication to the Neuro-Psychopharmacological College, Basel, July 4-7, 1960. Neuropharmacology, 1961, 2, 361-370.
[57]
Beaujard, M. Phacetoperane in Mental Retardation of Children. In: International Congress Series; Experta Medica, 1960; p. 100.
[58]
Bellander-Löfvenberg, S.; Osterman, E.; Brattemo, C.E. R P - 8228-Ett nytt psykoanalepticum. Nord. Psykiatr. Tidsskr., 1961, 15(2), 141-147.
[http://dx.doi.org/10.3109/08039486109167941]
[59]
Penteado Bueno, U.; Capp, A.B. Clinical results (consequent to the use of a new psychotonic in oligophrenic and epileptic and oligophrenic minors. Hospital Rio J., 1962, 62, 1003-1017.
[60]
Sivadon, P.; Chanoit, P.-F.; Azoulay, J. First clinical results with a new psychotonic, RP 8228. Méd. Psychol., 1959, 117, 536-541.
[61]
Ban, T.A.; St Laurent, J. The stimulating effect of RP 8228 on inactive psychiatric patients. J. Nutr., 1961, 3, 91-95.
[PMID: 13864565]
[62]
Brattemo, C.E. Experimentalpsykologisk undersökning med ett psykotonicum, RP. - 8228. Nord. Psykiatr. Tidsskr., 1961, 15(2), 147-154.
[http://dx.doi.org/10.3109/08039486109167942]
[63]
Leitch, A.; Seager, C.P. A trial of four anti-depressant drugs. Psychopharmacology (Berl.), 1963, 4(1), 72-77.
[http://dx.doi.org/10.1007/BF00429366] [PMID: 14050414]
[64]
Devic, M.; Revol, M.; Michel, F. [Apropos of the treatment of narcolepsy: trial use of a new psychoactive agent, R.P. 8228]. Lyon Med., 1962, 94, 1557-1562.
[PMID: 13885883]
[65]
Joncev, V.; Stefanova, E. Investigations on levophacetoperan effect upon higher nervous activity and memory. Folia Med. (Plovdiv), 1967, 9(6), 368-372.
[PMID: 4972459]
[66]
Beaujard, M. Phacetoperan in mental retardation in children. , 1963; pp. 165-167.
[67]
Faure, H.; Faure, M.L.; Stoppa, I. The activating effects of phacetoperan in childhood neuropsychiatry. J. Child Neuropediatrics Childhood Mental Hygiene, 1962, 10, 7-8.
[68]
Cutler, M.; Little, J.; Strauss, A. The effect of benzedrine on mentally deficient children. Am. J. Ment. Defic., 1940, 45, 59-65.
[69]
Morris, J.V.; Macgillivray, R.C.; Mathieson, C.M. The results of the experimental administration of amphetamine sulphate in oligophrenia. J. Ment. Sci., 1955, 101(422), 131-140.
[http://dx.doi.org/10.1192/bjp.101.422.131] [PMID: 14368214]
[70]
Raymond, F.; Janet, P. Review of les obsessions et la psychasthénie. Am. J. Psychol.,1903, 14(2), 262-264.
[http://dx.doi.org/10.2307/1412725]
[71]
Pitman, R.K. Janet’sObsessions and psychasthenia: A synopsis. Psychiatr. Q., 1984, 56(4), 291-314.
[http://dx.doi.org/10.1007/BF01064475] [PMID: 6399751]
[72]
Hubin, P.; Servais, J. study of the subjective effects of amphtamine in humans according to personality. Psychopharmacology (Berl.), 1968, 12(3), 239-249.
[http://dx.doi.org/10.1007/BF00403778]
[73]
Sutter, J.M.; Delpretti, G.M. Levophacetoperane (lidepran) in psychiatric therapeutics. Sud Med. Chir., 1962, 998-1005.
[74]
Fluyau, D.; Mitra, P.; Lorthe, K. Antipsychotics for amphetamine psychosis. A systematic review. Front. Psychiatry, 2019, 10, 740.
[http://dx.doi.org/10.3389/fpsyt.2019.00740] [PMID: 31681046]
[75]
Doyle, J.B.; Daniels, L.E. Narcolepsy; Results of treatment with ephedrine sulphate. J. Am. Med. Assoc., 1932, 98(7), 542-545.
[http://dx.doi.org/10.1001/jama.1932.02730330024006]
[76]
Yoss, R.E.; Daly, D. Treatment of narcolepsy with Ritalin. Neurology, 1959, 9(3), 171-173.
[http://dx.doi.org/10.1212/WNL.9.3.171] [PMID: 13632876]
[77]
Janota, O. Treatment of Narcolepsy With Ephedrine. Proceedings of the Proceedings of the work of the Neuro-Psychiatric Section of the 14th Congress of Polish Physicians and Naturalists, Poznan, 1933.
[78]
Mondenard, J. Doping: Piperidines: Lidépran, Mératran, Ritalin. Odds and ends without great effects. Médecine du sport, 1991, 65, 00145-00148.
[79]
Delbeke, F.T.; Debackere, M. Isolation and detection of methylphenidate, phacetoperane and some other sympatomimetic central nervous stimulants with special reference to doping. J. Chromatogr. A, 1975, 106(2), 412-417.
[http://dx.doi.org/10.1016/S0021-9673(00)93853-6] [PMID: 239015]

Rights & Permissions Print Cite
Article Metrics
21
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy